Biodexa Pharmaceuticals (STU:5MP2) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2025)

What is Biodexa Pharmaceuticals LT-Debt-to-Total-Asset?

Biodexa Pharmaceuticals STU:5MP2 10 LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus rates STU:5MP2 with a GF Score™ of 10/100 and a GF Value™ of €95,593.41.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Biodexa Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.00.

Biodexa Pharmaceuticals's long-term debt to total assets ratio declined from Dec. 2024 (0.01) to Dec. 2025 (0.00). It may suggest that Biodexa Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Biodexa Pharmaceuticals (STU:5MP2) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Biodexa Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Biodexa Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals LT-Debt-to-Total-Asset Chart

Biodexa Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.08

0.03

0.01

0.00

Biodexa Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.02	0.01	0.00	0.00

10GF Score

Biodexa Pharmaceuticals PLC STU:5MP2

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Biodexa Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Biodexa Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0	/	20.783
	=

Biodexa Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	0	/	20.783
	=

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Biodexa Pharmaceuticals (STU:5MP2) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Biodexa Pharmaceuticals and its competitors.

Is Biodexa Pharmaceuticals' LT-Debt-to-Total-Asset too high?

Biodexa Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.00. Overall, Biodexa Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Biodexa Pharmaceuticals' LT-Debt-to-Total-Asset compare to CASIF and OGEN?

Biodexa Pharmaceuticals' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Biodexa Pharmaceuticals stock overvalued right now?

Biodexa Pharmaceuticals (STU:5MP2) has a current LT-Debt-to-Total-Asset of 0.00. The stock's GF Value™ is €95,593.41, compared to a current price of €110,400.00 — trading 15.5% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Biodexa Pharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Biodexa Pharmaceuticals (STU:5MP2), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (STU:5MP2) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of €110,400.00 is trading 15.5% above its estimated GF Value™ of €95,593.41.

Key valuation signals for STU:5MP2:

LT-Debt-to-Total-Asset: 0.00
GF Value™: €95,593.41 vs. price of €110,400.00 (15.5% above fair value)
GF Score™: 10/100

No single metric tells the full story. See the STU:5MP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CASIF OGEN ELOX CPMV VBIO JAGX BBLG PKTX SLXN HEPA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges BDRX:USA

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ

Website https://www.biodexapharma.com

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

10GF Score

Get the complete analysis for STU:5MP2

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€110,400.00

Price

€95,593.41

GF Value

View STU:5MP2 Analysis

See LT-Debt-to-Total-Asset data for all stocks →